Suppr超能文献

LC-MS 法确证检测马血浆中的连续性促红细胞生成素受体激活剂和促红细胞生成素类似物用于兴奋剂检测。

Confirmatory analysis of continuous erythropoietin receptor activator and erythropoietin analogues in equine plasma by LC-MS for doping control.

机构信息

School of Veterinary Medicine, University of Pennsylvania, New Bolton Center Campus, 382 West Street Road, Kennett Square, Pennsylvania 19348, United States, Pennsylvania Equine Toxicology and Research Center, West Chester University, West Chester, Pennsylvania 19382, United States, and Equine Drug Testing and Research Program, College of Veterinary Medicine, Cornell University, 925 Warren Drive, Ithaca, New York 14850, United States.

出版信息

Anal Chem. 2010 Nov 1;82(21):9074-81. doi: 10.1021/ac102031w. Epub 2010 Oct 14.

Abstract

Continuous erythropoietin receptor activator (CERA) is the third generation of recombinant human erythropoietin (rhEPO) medication that retains the effect of promoting red blood cell production but has longer duration of action in the body. CERA, rhEPO, and darbepoetin alpha (DPO) can be misused to enhance performance in both human and equine athletes. To deter such misuse, a very selective and sensitive liquid chromatography-tandem mass spectrometric (LC-MS/MS) method has now been developed for identification of CERA, rhEPO, and DPO in equine plasma. The method employs a new signature tryptic peptide, T8 ((54)MEVGQQAVEVWQGLALLSEAVLR(76), common to the three proteins), and improved immunoaffinity extraction. The analytes were extracted by anti-rhEPO antibodies from plasma samples that were pretreated with polyethylene glycol (PEG) 6000. The extracted analytes were digested by trypsin and analyzed by LC-MS/MS. The limit of identification was 0.5 ng/mL for CERA, 0.2 ng/mL for rhEPO, and 0.1 ng/mL for DPO in equine plasma; the limit of detection was 0.3 ng/mL for CERA, 0.1 ng/mL for rhEPO, and 0.05 ng/mL for DPO. Specificity of the method was assessed via BLAST and SEQUEST protein database searches, and the T8 is extremely specific at both peptide and product ion levels for the identification of CERA, rhEPO, and DPO. This method was successful in identifying CERA and DPO in plasma samples collected from research horses post the drug administrations. It provides a useful tool in the fight against blood doping with CERA, rhEPO, and DPO in racehorses. Additionally, the following two technical approaches adopted in this study may also be helpful in protein identifications and biomarker discoveries in a broad scope: precipitating plasma proteins with PEG 6000 to improve immunoaffinity extraction efficiency of the target proteins and making a large and more lipophilic peptide detectable at low concentrations by increasing its solubility in the sample solvent.

摘要

连续红细胞生成素受体激动剂(CERA)是第三代重组人红细胞生成素(rhEPO)药物,保留了促进红细胞生成的作用,但在体内的作用持续时间更长。CERA、rhEPO 和达贝泊汀 α(DPO)可被滥用于提高人类和赛马运动员的表现。为了阻止这种滥用,现在已经开发出一种非常选择性和灵敏的液相色谱-串联质谱(LC-MS/MS)方法来鉴定马血浆中的 CERA、rhEPO 和 DPO。该方法采用了一种新的特征性胰蛋白酶肽,T8((54)MEVGQQAVEVWQGLALLSEAVLR(76)),与三种蛋白质共有)和改进的免疫亲和提取。该分析物通过抗 rhEPO 抗体从用聚乙二醇(PEG)6000 预处理的血浆样品中提取。提取的分析物用胰蛋白酶消化,并通过 LC-MS/MS 分析。CERA、rhEPO 和 DPO 在马血浆中的鉴定限分别为 0.5ng/mL、0.2ng/mL 和 0.1ng/mL;检测限分别为 0.3ng/mL、0.1ng/mL 和 0.05ng/mL。通过 BLAST 和 SEQUEST 蛋白质数据库搜索评估方法的特异性,T8 在肽和产物离子水平上对 CERA、rhEPO 和 DPO 的鉴定非常特异。该方法成功地鉴定了给药后从研究马采集的血浆样品中的 CERA 和 DPO。它为对抗赛马中 CERA、rhEPO 和 DPO 的血液兴奋剂提供了有用的工具。此外,本研究采用的以下两种技术方法也可能有助于广泛的蛋白质鉴定和生物标志物发现:用 PEG 6000 沉淀血浆蛋白以提高目标蛋白的免疫亲和提取效率,以及通过增加样品溶剂中的溶解度使大而疏水性更强的肽在低浓度下变得可检测。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验